The impact of COVID-19 on patients with asthma.
The impact of COVID-19 on patients with asthma.
复制标题
DOI：
10.1183/13993003.03142-2020
复制
发表时间：
2021-03
期刊：
影响因子：
--
通讯作者：
Soriano JB
中科院分区：
文献类型：
--
作者：
Izquierdo JL;Almonacid C;González Y;Del Rio-Bermudez C;Ancochea J;Cárdenas R;Lumbreras S;Soriano JB
2019冠状病毒病（COVID-19）的严重程度与某些慢性疾病的存在之间存在关联。然而，与流感和其他病毒不同，COVID-19对哮喘患者的疾病负担不太明显。了解COVID-19对哮喘患者的影响。通过SAVANA Manager临床平台使用大数据分析和人工智能，我们分析了2020年1月1日至5月10日哮喘患者的临床数据。在71182名哮喘患者中，1006人（1.41%）患有COVID-19。 与未患COVID-19的哮喘患者相比，患有哮喘和COVID-19的患者年龄明显更大（55岁对42岁），主要是女性（66%对59%），吸烟更频繁，高血压、血脂异常、糖尿病和肥胖的患病率更高。 过敏相关因素如鼻炎和湿疹在COVID-19哮喘患者中较少见（p<0.001）。此外，在需要住院的COVID-19患者中观察到这些合并症的患病率较高。与未住院患者相比，因COVID-19需要住院的患者中吸入性皮质类固醇（ICS）的使用率较低（48.3% vs 61.5%; OR 0.58，95% CI 0.44-0.77）。尽管接受生物制剂治疗的患者（n=865; 1.21%）在耳、鼻和喉水平显示出严重程度增加和更多的合并症，但这些患者的COVID-19相关住院率相对较低（0.23%）。哮喘和COVID-19患者年龄较大，由于合并症相关因素，风险增加。ICS和生物制剂通常是安全的，可能与预防严重COVID-19感染的保护作用有关。哮喘患者因COVID-19住院治疗的风险增加在很大程度上与年龄和相关合并症相关。ICS和生物制剂可能与针对COVID-19最严重表现的保护作用有关。https://bit.ly/37yhr5b
An association between the severity of coronavirus disease 2019 (COVID-19) and the presence of certain chronic conditions has been suggested. However, unlike influenza and other viruses, the disease burden of COVID-19 in patients with asthma has been less evident. To understand the impact of COVID-19 in patients with asthma. Using big-data analytics and artificial intelligence through the SAVANA Manager clinical platform, we analysed clinical data from patients with asthma from January 1 to May 10, 2020. Out of 71 182 patients with asthma, 1006 (1.41%) suffered from COVID-19. Compared to asthmatic individuals without COVID-19, patients with asthma and COVID-19 were significantly older (55 versus 42 years), predominantly female (66% versus 59%), smoked more frequently and had higher prevalence of hypertension, dyslipidaemias, diabetes and obesity. Allergy-related factors such as rhinitis and eczema were less common in asthmatic patients with COVID-19 (p<0.001). In addition, higher prevalence of these comorbidities was observed in patients with COVID-19 who required hospital admission. The use of inhaled corticosteroids (ICS) was lower in patients who required hospitalisation due to COVID-19, as compared to non-hospitalised patients (48.3% versus 61.5%; OR 0.58, 95% CI 0.44–0.77). Although patients treated with biologics (n=865; 1.21%) showed increased severity and more comorbidities at the ear, nose and throat level, COVID-19-related hospitalisations in these patients were relatively low (0.23%). Patients with asthma and COVID-19 were older and at increased risk due to comorbidity-related factors. ICS and biologics are generally safe and may be associated with a protective effect against severe COVID-19 infection. The increased risk of hospitalisation due to COVID-19 in patients with asthma is largely associated with age and related comorbidities. ICS and biologics may be associated with a protective effect against the most severe manifestations of COVID-19. https://bit.ly/37yhr5b
登录
查看更多内容
影响因子：
158.5
作者：
Li, Qun;Guan, Xuhua;Feng, Zijian
通讯作者：
Feng, Zijian
DOI：
10.1164/rccm.201803-0461oc
发表时间：
2019-02-15
影响因子：
24.7
作者：
Pineros, Yanaika S. Sabogal;Bal, Suzanne M.;Lutter, Rene
通讯作者：
Lutter, Rene
影响因子：
9.1
作者：
Liu S;Zhi Y;Ying S
通讯作者：
Ying S
影响因子：
24.3
作者：
Guan, Wei-jie;Liang, Wen-hua;He, Jian-xing
通讯作者：
He, Jian-xing
DOI：
10.1164/rccm.202003-0821oc
发表时间：
2020-07-01
影响因子：
24.7
作者：
Peters, Michael C.;Sajuthi, Satria;Fahy, John, V
通讯作者：
Fahy, John, V